Hajiaghamohammadi AA et al. Treatment of Non Alcoholic Fatty Liver Disease e d ) i Table 4. Strength of Treatment Effects in Three Groups of Intervention r % e ( c . µ1 µ2 SD Effect Size ) ) ly o ) ) 4 ) ) .6 g ) 3 7 . N 3 6 1 i 2 . . 9 7 . . 0 r . 3 0 Pioglitazone t 7 9 6 t 2 0 3 s 7 6 5 ( ( , 2 ( ( ( 4 o ( ( 0 0 G 7 4 3 T P 5 1 1 1 9 2 4 Weight, kg 76.95 77.82 9.25 - 0.09 ; e c ) n a 2 a BMI , kg/m 27.36 27.67 1.68 - 0.18 a % t R ( I ) s . ) - 5 ) i 5 ) ) 6 s a A o 4 ) FBS , mmol/L 95.45 84.91 6.07 1.74 5 . 1 9 . e . ) . . 4 N 5 . 4 r 4 9 9 M . 0 4 2 5 5 5 e ( ( n ( 4 ( 4 4 O r ( ( i a ( 8 l TG , mg/dL 252.18 224.09 49.94 0.56 2 0 3 H P 1 1 9 1 9 8 2 u s n a i CHOL , mg/dL 195.68 178.64 33.15 0.51 ) r % o f ( a AST , IU/L 55.09 37.59 9.08 1.93 . x ) ) ) ) ) e o 5 5 ) 8 2 ) 8 ) d 1 4 5 6 .8 .1 N 2 . . . . 4 n a . ALT , IU/L 77.45 52.27 16.53 1.52 8 8 5 3 7 2 i t . 4 6 (3 (6 s 1 6 4 5 6 t ( 3 ( ( 3 ( o ( ( 5 1 n 5 0 2 4 e P 7 1 1 1 8 1 2 4 Insulin Levels, 14.20 11.76 3.52 0.69 m s mmol/L s ) e /L (% s ) s 1 a U . a HOMA-IR 2.89 2.12 0.80 0.95 ,I o ) 9 ) . ) l ) 0 9 0 e a N 0 7 0 ) 0 0 ) d 9 . 9 1 1 ) Metformin T e ( ( ( ( o 0 9 0 3 ( ( S r ( 4 ( 2 0 2 m A P 2 0 2 2 2 0 6 2 s i Weight, kg 76.91 75.46 9.71 0.15 s a ) t s 2 BMI, kg/m 27.53 27.00 1.91 0.28 % o ( e . ) 1 o ) m ) ) 3 9 ) ) FBS, mmol/L 95.09 87.41 6.14 1.25 7 . ) o 7 ) 8 N 9 8 . 2 . 2 0 . . 2 1 . h t 2 0 1 . 7 9 . 8 8 , 7 8 s ( 8 ( 1 ( 2 1 9 ( ( R TG, mg/dL 248.36 222.73 51.79 0.49 o ( ( ( 4 2 -I 0 6 8 P 1 6 2 2 1 4 5 1 A M CHOL, mg/dL 193.00 175.86 33.40 0.51 O ) /L % H ; ( AST, IU/L 54.86 42.50 10.65 1.16 r U . ,I o ) ) ) ) a g 0 0 0 0 a N 10 ) u 0 ) 0 ) 0 ) ALT, IU/L 78.36 60.95 17.04 1.02 1 1 1 s ( T e ( 0 ( 0 ( 0 0 ( ( ( ( L r d 2 2 2 6 A P 2 0 2 0 2 0 6 0 o Insulin Levels, 14.17 12.06 3.78 0.56 o l e b mmol/L n ) n g i n i % o n i ( r z l m t . HOMA-IR 2.87 2.24 0.87 0.72 a a s a r o t ) ) t ) ) a fto .)72 ) 8 3 3 .7 ,f N li ) o . 2 1 7 m ) . . 2 . T 0 9 S 8 8 liy .138 t g /1 2 Silymarin e 72 8 3 (6 B s 6 7 ( o 3 ( ( 6 F o ( ( i ( S ( 0 6 ; 5 M 6 4 l L P 7 1 6 1 7 5 2 P o Weight, kg 77.00 77.09 9.51 - 0.01 d r / n e g t o ) s 2 i BMI, kg/m 27.44 27.48 1.67 - 0.02 t % e m ( ) l n ) ) ) , . ) ) 6 5 o e a 9 5 1 5 v o 4 4 .5 h 0 . 5 . FBS, mmol/L 95.95 93.95 5.93 0.34 L 9 . . 4 ,c r ) ) . 5 N 5 9 4 e 0 0 0 O 4 4 (5 L t 5 5 e 5 5 ( ( 4 ( ( n H r ( ( ( O TG, mg/dL 254.18 239.09 54.38 0.28 I 1 1 3 0 2 0 0 C P 1 1 9 1 1 1 3 3 f H o C ; s e CHOL, mg/dL 191.68 181.32 33.12 0.31 p s ) u a r o % r ( e AST, IU/L 56.00 37.77 9.92 1.84 . f G s o ) e ) ) ) n e N 0 a 0 0 0 ALT, IU/L 78.73 53.05 16.85 1.52 r r 0 t 0 ) 0 ) 0 ) ) t 1 1 1 1 h s ( ( 0 ( 0 ( 0 0 o T ( ( ( ( o 2 2 2 6 n 0 i Insulin Levels, 14.19 13.50 3.76 0.18 n P 2 0 2 0 2 0 6 i m s r a mmol/L L e ) e t d t / % e a ( g t HOMA-IR 2.90 2.70 0.89 0.22 . m r ) ) ) ) a m o a 0 r 0 0 0 p , N 10 ) a 0 ) 0 ) 0 ) s a 1 1 1 a P ( Abbreviations: ALT, alanineaminotransferase; AST, aspartate aminotrans- e ( 0 ( 0 ( 0 0 a ( ( ( ( , r e G 2 2 2 6 T T P 2 0 2 0 2 0 6 0 S ferase; BMI, body mass index; CHOL, cholesterol; FBS, fasting blood sugar; m A o ; S HOMA-IR, homeostasis model assessment index for insulin resistance; TG, e f ) s o a triglyceride. % r s ( e e . f ) g s o ) ) ) ) ) 6 n n 6 3 5 N 4 . . a 0 3 0 a ) 5 / 6 6 r h t ) 10 ) 0 . 5 6 1 . 9 t ed in relation to their uptake. Given the fact that it seems s 3 8 C 0 ( 0 ( ( 3 1 ( 4 o ( ( o ( ( ( l 2 2 3 n 9 a P 0 2 0 8 2 3 1 3 6 i NASH is a part of metabolic syndrome, the effects of these c L / i l m n a i o ) drugs on lipid profile, blood sugar, serum insulin level, l e C m (% - n i n . ) ) and HOMA Index were also examined in addition to their ) ) n m o ) ) ) o ) 8 ) 7 3 1 3 7 7 3 a , 2 1 7 . . . 2 . . l N a 7 . 2 N 8 . . 7 8 9 2 2 a . 7 2 effects on decrease in hepatic aminotransferases. In this 1 2 7 d S 6 5 7 7 7 ( , e 2 ( 3 ( 2 ( ( ( T ( n B r ( ( 8 5 3 7 6 8 L a F P 7 1 5 1 1 6 1 1 4 study, significant differences were observed between av- A l : a s c i n erage biochemical indices before and after intervention n l l l l o i a a a ca it l c c c (drug consumption) in patients with NASH in all three C i i i i a in iv . l n l n l n l i i i 3 a l a l a l a l e c c c c c c c -c r treatment groups. Metformin and pioglitazone exhibited e i - i - i - i l n b n n n n n n n i i i i b o o o o b l l l l large effects on FBS, and moderate effects on TG, choles- a C N C N C N C N A T a 4 Hepat Mon. 2012;12(8):e6099